A patient is taking aspirin to help prevent myocardial infarction and is experiencing moderate gastrointestinal upset. The nurse will contact the patient’s provider to discuss changing from aspirin to which drug?

A) Myasthenia gravis (MG):
Weakness of the extremities and diplopia (double vision) are hallmark symptoms of myasthenia gravis, an autoimmune disorder that affects the neuromuscular junction. In MG, antibodies attack acetylcholine receptors, leading to muscle weakness that worsens with activity and improves with rest. The weakness typically affects voluntary muscles, including those responsible for eye movement, which leads to symptoms such as diplopia and ptosis (drooping eyelids).

B) Multiple sclerosis (MS):
Multiple sclerosis involves the demyelination of neurons in the central nervous system, leading to a variety of neurological symptoms. While MS can cause weakness and visual disturbances, the typical symptoms of MS include fatigue, muscle spasticity, ataxia, and sensory deficits. Diplopia can occur in MS but is usually accompanied by other neurological signs such as numbness, tingling, or loss of coordination.

C) Cerebral palsy (CP):
Cerebral palsy is a group of disorders affecting movement and posture due to non-progressive brain injury or abnormal brain development, often occurring in early childhood. While CP can cause muscle weakness and coordination issues, it does not typically present with diplopia. Instead, it often involves spasticity, motor impairment, and difficulty with fine motor tasks.

D) Parkinson disease (PD):
Parkinson disease is characterized by tremors, bradykinesia (slowness of movement), rigidity, and postural instability. While PD can lead to muscle weakness and visual issues like blurred vision, it is not typically associated with diplopia as a primary symptom. The hallmark motor symptoms are primarily related to tremor and difficulty initiating movements rather than generalized weakness and double vision.

A) It decreases the activity of norepinephrine receptor sites: Cholinergic agonists specifically act on acetylcholine receptors, not norepinephrine receptors. Norepinephrine is associated with the sympathetic nervous system and its receptors (alpha and beta), whereas cholinergic agonists affect the parasympathetic system through acetylcholine receptors.
B) It increases the activity of acetylcholine receptor sites: This is the correct answer. Cholinergic agonists work by stimulating acetylcholine receptors (both muscarinic and nicotinic), thereby enhancing the action of acetylcholine. This can lead to various effects such as decreased heart rate, increased digestion, and muscle contraction, as part of the parasympathetic nervous system response.
C) It decreases the activity of GABA receptor sites: GABA (gamma-aminobutyric acid) is an inhibitory neurotransmitter that acts on GABA receptors, not acetylcholine receptors. Cholinergic agonists have no direct effect on GABA receptor activity.
D) It increases the activity of dopamine receptor sites: Dopamine is a neurotransmitter primarily involved in the reward system, motor control, and mood regulation. Cholinergic agonists do not directly affect dopamine receptors. Instead, they target acetylcholine receptors, which are part of the parasympathetic nervous system.